Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 81

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 81
---
118,330 |     |  6 | % |     | Uterine corpus        |     |  67,880 |     |  7 | % |
| Melanoma of the skin  |     |  59,170 |     |  6 | % |     | Melanoma of the skin  |     |  41,470 |     |  5 | % |
| Kidney & renal pelvis |     |  52,380 |     |  5 | % |     | Thyroid               |     |  31,520 |     |  3 | % |
| Non-Hodgkin lymphoma  |     |  44,590 |     |  4 | % |     | Non-Hodgkin lymphoma  |     |  36,030 |     |  4 | % |
| Oral cavity & pharynx |     |  41,510 |     |  4 | % |     | Kidney & renal pelvis |     |  29,230 |     |  3 | % |
| Leukemia              |     |  36,450 |     |  4 | % |     | Pancreas              |     |  31,910 |     |  3 | % |
| Pancreas              |     |  34,530 |     |  3 | % |     | Leukemia              |     |  26,320 |     |  3 | % |
| All sites             |     | 983,160 |     |    |   |     | All sites             |     | 934,870 |     |    |   |

ACS Facts & Figures, 2024

The U.S. estimated incidence, deaths and five-year survival rate of cancer patients responsive to radiation therapy is significant (ACS Facts & Figures, 2024). The top cancers responsive to radiation are shown, based on the number of newly diagnosed patients. The incidence rates for some cancers are increasing by approximately 1-2% per year in the U.S. The number of newly diagnosed patients is significant and growing due to the aging of the population and improved diagnostic techniques.

The cancers listed above illustrate the opportunity presented for radiation sensitizers. Of note is the low five-year survival of pancreas, brain, lung and esophagus cancers—all are candidates for Shuttle Pharma’s pipeline of radiation sensitizing compounds.